SCHEMBL3019313

SCHEMBL3019313

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(C(C)(C)C)cc4)CC3)n2)cc(OC)c1OC

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.47
USP2 O75604 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015597 0.91 HSD11B1 (0.47) HSD11B1USP2MAPTRECQLHSD17B10
SCHEMBL3008375 0.90 ALDH1A1 (0.47) USP2MAPTRECQLHSD17B10MEN1
SCHEMBL3002725 0.89 HSD11B1 (0.53) HSD11B1USP2MAPTRECQLHSD17B10
SCHEMBL3007158 0.89 MAPT (0.56) USP2MAPTRECQLHSD17B10L3MBTL1
SCHEMBL3022395 0.89 USP2 (0.45) USP2MAPTRECQLHSD17B10KMT2A
SCHEMBL3017960 0.89 MAPT (0.45) USP2MAPTRECQLHSD17B10KMT2A
SCHEMBL3008714 0.88 USP2 (0.45) USP2MAPTRECQLHSD17B10MEN1
SCHEMBL3018982 0.88 TSHR (0.51) HSD11B1USP2MAPTRECQLHSD17B10
SCHEMBL3013960 0.87 USP2 (0.46) USP2MAPTRECQLHSD17B10KMT2A
SCHEMBL3002600 0.87 KMT2A (0.47) HSD11B1USP2MAPTRECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD11B1 1034/4885USP2 1831/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.